Novartis develops and manufactures innovative drugs. Key areas of drug development are oncology, immunology, neuroscience, and cardiovascular, renal, and metabolic. It also has an established medicines business, which includes off-patent franchises. The company sells its products globally, with the United States constituting close to one-third of total revenue.
Company facts
| Company | Novartis AG |
|---|---|
| Symbol | NVS |
| Exchange | XNYS |
| Sector | Healthcare |
| Industry | Drug Manufacturers - General |
| Market cap | $261.31B (Massive market data, 2026-09-10) |
| Employees | 75,267 |
| Country | Switzerland |
| Website | https://www.novartis.com |
Trading — Novartis AG
| Last price | $137.34 |
|---|---|
| Change | -0.10% |
| Previous close | $137.48 |
| Day range | $137.00 – $139.55 |
| 50-day average | $155.62 |
| 200-day average | $149.72 |
| Average volume | 1,818,933 |
Price basis: 2026-09-11T20:38:02.873369+00:00
Valuation and financial health
| Earnings per share | $3.55 |
|---|---|
| Price / book | 3.61 |
| Price / cash flow | 21.89 |
| Enterprise value / EBITDA | 21.51 |
| Enterprise value / sales | 5.46 |
| Debt / equity | 0.22 |
| Current ratio | 0.90 |
| Dividend yield | 2.48% |
| Free cash flow | $9.69B |
| Cash ratio | 0.22 |
| Enterprise value | $271.85B |
Reported 2026-09-10
Earnings
| Report date | 2026-10-27 |
|---|---|
| Session | Pre Market |
| Fiscal quarter ending | Sep/2026 |
| EPS estimate | $2.24 |
| Year-ago EPS | $2.25 |
| Analyst estimates | 5 |
Source: Nasdaq.com public earnings calendar
Other Healthcare companies
Live data
Live quotes, options positioning, insider and congressional filings for NVS are on the IntelTrends dashboard.